Phathom Pharmaceuticals, Inc. - Common Stock (PHAT)
6.2600
-0.0800 (-1.26%)
Phathom Pharmaceuticals Inc is a biopharmaceutical company focused on developing innovative therapies for gastrointestinal diseases, particularly in the area of acid-related disorders
The company is dedicated to addressing unmet medical needs through its research and development efforts, aiming to provide patients with effective treatment options. By leveraging their expertise in drug development and clinical research, Phathom seeks to bring new molecules to market that enhance patient care and improve health outcomes in the realm of digestive health.
Investing in biotechnology stocks offers a unique opportunity for individuals looking to gain exposure to one of the most dynamic and innovative sectors of the market.
PHAT stock results show that Phathom Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
PHAT stock results show that Phathom Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
